<DOC>
	<DOCNO>NCT01069627</DOCNO>
	<brief_summary>This study investigate efficacy safety bevacizumab + fotemustine patient stage IV melanoma , previously untreated chemo- immunotherapy metastatic disease . Patients receive Avastin ( 15mg/kg intravenously [ IV ] ) Day 1 every 3 week cycle , combination fotemustine ( 100mg/m² IV ) Days 1 , 8 15 , follow 4 week rest , follow 100mg/m² IV every 3 week 4-6 cycle . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Fotemustine Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fotemustine</mesh_term>
	<criteria>cutaneous malignant melanoma ; advanced , inoperable stage IV melanoma ; measurable and/or evaluable site metastasis . prior chemotherapy and/or IFN/IL2 base immunotherapy metastatic disease ; prior malignancy within past 5 year , exception cure nonmelanoma skin cancer , situ cancer cervix ; clinically significant cardiovascular disease ; ongoing treatment aspirin ( &gt; 325mg/day ) medication know predispose gastrointestinal ulceration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>